Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
Covered in this story
What has happened since
- Vertex Pharmaceuticals is up 13.7% since this was published, 80 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $CRNX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crinetics Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.